Clinical Trial

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HRS9531 Injection in Adolescents With Obesity

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The aim of this trial is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of HRS9531 injection compared with placebo in adolescents with obesity
Protocol Amendment History 2 changes
critical Recruitment opened 2026-08-01
notable Primary completion pushed: 2027-01 -> 2027-02 2026-08-01
Trial Details
NCT Number NCT07559136
Lead Sponsor Fujian Shengdi Pharmaceutical Co., Ltd.
Conditions Overweight and Obesity
Enrollment 48 participants
Start Date 2026-06-12
Primary Completion 2027-02 (estimated)
Study Completion 2027-03 (estimated)
Updated on ClinicalTrials.gov 2026-07-31